MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast Cancer

Model scores of the 29,894 trials active now.

Model score 13% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (1,938 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2013-07-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: breast cancerher2patients musttransplantchemotherapy
  Phrases that lowered it: patients whommcriteria patientspatients withbased on
• Phase: 1 (lowers risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 10.8% (lowers risk) · Drug's FDA history
• Disease area, cancer: Yes (raises risk) · Disease area
• Trials the sponsor started in the prior 2 years: 3 (raises risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Sponsor's past trials: 1 (raises risk) · Sponsor's track record
• Maximum age: not given (raises risk) · Who can join
• Has a data monitoring committee: No (lowers risk) · Design
• Drug's FAERS reports marked serious: 93.9% (raises risk) · Drug's FDA history
• Disease area, dermatology: Yes (raises risk) · Disease area
• Primary purpose: treatment (raises risk) · Design
• Number of arms: 1 (raises risk) · Design
• Responsible party: sponsor (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers NCT00911898 · started 2009 · scored riskier than 31% of active trials completed
• A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer NCT01304784 · started 2011 · scored riskier than 31% of active trials completed
• Evaluate Safety, Tolerability and Pharmacokinetics of HLX22 in Patients With Advanced Solid Tumors Overexpressing HER2 NCT03916094 · started 2019 · scored riskier than 22% of active trials completed
• Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer NCT01873833 · started 2013 · scored riskier than 78% of active trials terminated
• Compare Efficacy, Safety and Immunogenicity of HLX02 and Herceptin in Previously Untreated HER2 +Overexpressing Metastatic Breast Cancer NCT03084237 · started 2016 · scored riskier than 25% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.